Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Sharyn Katz, MD, MTR, Associate Professor at the University of Pennsylvania Perelman School of Medicine
Videos
Radiology of COVID: Dealing With Diagnostic Ambiguity
09/28/2022
Sharyn Katz, MD, MTR, provides an overview on the potential for diagnostic ambiguity in the radiology of Covid-19, a topic she presented at the 2022 GDU Lung Cancers virtual meeting.
Sharyn Katz, MD, MTR, provides an overview on the potential for diagnostic ambiguity in the radiology of Covid-19, a topic she presented at the 2022 GDU Lung Cancers virtual meeting.
Sharyn Katz, MD, MTR, provides...
09/28/2022
Oncology

Advertisement

Thomas Martin, MD, University of California, San Francisco
Videos
Ciltacabtagene Autoleucel Maintains Deep and Durable Responses in MM With Longer Follow-up: CARTITUDE-1
09/28/2022
Thomas Martin, MD, discusses an updated analysis of the CARTITUDE-1 trial, in which ciltacabtagene autoleucel maintained deep and durable responses in heavily pretreated patients with MM at a follow-up of 28 months.
Thomas Martin, MD, discusses an updated analysis of the CARTITUDE-1 trial, in which ciltacabtagene autoleucel maintained deep and durable responses in heavily pretreated patients with MM at a follow-up of 28 months.
Thomas Martin, MD, discusses an...
09/28/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania
Videos
Immune Checkpoint Inhibitors Improve Treatment Outcomes in Malignant Pleural Mesothelioma
09/22/2022
Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/22/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology at the Abramson Cancer Center at the University of Pennsylvania
Videos
Potential Impact of Immune Checkpoint Inhibitors in Thymic Malignancies
09/22/2022
Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/22/2022
Oncology

Advertisement

Pasi Jänne, MD, Dana-Farber Cancer Institute
Videos
Trastuzumab Deruxtecan for HER2-Mutant Non-Small Cell Lung Cancer
09/21/2022
Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.
Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.
Pasi Jänne, MD, shares insights...
09/21/2022
Oncology
Corey Langer, MD, Director of Thoracic Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania
Videos
Is There a Role for Tumor Treatment Fields in Advanced NSCLC?
09/21/2022
Corey Langer, MD, provides an overview on the potential of tumor treatment fields for the treatment of advanced NSCLC, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an overview on the potential of tumor treatment fields for the treatment of advanced NSCLC, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.
Corey Langer, MD, provides an...
09/21/2022
Oncology
David Tougeron, MD, Poitiers University Hospital
Videos
Second-Line FOLFIRI Plus Immune Checkpoint Inhibitors Yields No Survival Benefit in Advanced Gastric or GEJ Cancers
09/20/2022
David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.
David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.
David Tougeron, MD, reviews...
09/20/2022
Oncology

Advertisement

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center
VIDEOS
Enfortumab Vedotin Plus Pembrolizumab Induces High Response Rates in Cisplatin-Ineligible Patients With Urothelial Cancer
09/20/2022
Allison Casey
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.
Jonathan Rosenberg, MD, reviews...
09/20/2022
Oncology
Matthew Goetz, MD, Mayo Clinic
VIDEOS
Lasofoxifene vs Fulvestrant for ESR1-Mutated Metastatic Breast Cancer With Progression on CDK4/6 Inhibitors
09/15/2022
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.
Matthew Goetz, MD, highlights...
09/15/2022
Oncology
Keiichi Fujiwara, MD, PhD, Saitama Medical University International Medical Center
Videos
Maintenance Chemotherapy With Tegafur-Uracil vs Observation for Locally Advanced Cervical Cancer
09/15/2022
Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.
Keiichi Fujiwara, MD, PhD,...
09/15/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use